Business Context and Reporting Period
This Form 8-K was filed by Rocket Pharmaceuticals, Inc. (RCKT) on December 13, 2023, reporting events occurring on December 7, 2023. The filing addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of R. Keith Woods to the Board of Directors, effective December 7, 2023. Mr. Woods brings over 30 years of biopharmaceutical experience, most recently serving as Chief Operating Officer for argenx SE and previously holding senior roles at Alexion Pharmaceuticals, Roche, Amgen, and Eisai.
Compensatory Arrangements and Governance
Upon his appointment, Mr. Woods received two stock option grants pursuant to the Company's non-employee director compensation policy:
- First Option Grant: 20,522 shares vesting in equal monthly installments over three years.
- Second Option Grant: 11,960 shares fully vesting on the first anniversary of the grant date.
Both grants have an exercise price equal to the closing market price on the date of grant and are subject to continued service. Mr. Woods also entered into the Company's standard indemnification agreement. The filing confirms no related person transactions or family relationships exist between Mr. Woods and other directors or officers.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 32,482 total options granted to Mr. Woods.
- Review the Company's non-employee director compensation policy to understand the rationale for the grant sizes.
- Confirm Mr. Woods' specific areas of expertise (commercial operations, market access) align with the Company's current strategic needs.
- Check for any subsequent filings regarding the composition of Board committees following this appointment.